Toxicity from the recreational use of 1-benzylpiperazine

References

• D Fisher. Human guinea pigs for party pill. New Zealand Herald 27 November, 2005;
   Google Scholar
• C Wilkins, M Girling, P Sweetsur, T Huckle, and J Huakau. Legal Party Pill Use in New Zealand: Prevalence of Use, Availability, Health Harms, and “Gateway Effects” of Benzylpiperazine and Triflurophenylmethylpiperazine (TFMPP) 2006, Centre for Social and Health Outcome Research and Evaluation. Auckland, New Zealand: Massey University; 2006.
   Google Scholar
• Schedules of Controlled Substances; Placement of 2,5-dimethoxy-4-(n)propothiophenethylamine and N-Benzylpiperazine into Schedule 1 of the Controlled Substances Act. Final rule. DEPARTMENT OF JUSTICE. Drug Enforcement Agency. FRDoc 04–6110 (Federal Register: March 18, 2004 [volume 69, Number 53]) [Rules and Regulations] [Page 12794–7] From the Federal Register Online via GPO Access.
   Google Scholar
• C Bye, A Munroe-Faure, A Peck, and P Young. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973; 6:163–169.
   PubMed Web of Science ®Google Scholar
• K Magyar, MI Fekete, K Tekes, and TL Torok. The action of trelebet, a new antidepressive agent on [3H]noradrenaline release from rabbit pulmonary artery. Eur J Pharmacol 1986; 130 (3):219–227.
   PubMed Web of Science ®Google Scholar
• B Malomvolgyi, L Tothfalusi, K Tekes, and K Magyar. Comparison of serotonin agonistic and antagonistic activities of a new antidepressant agent Trelibet (EGYT-475) and its metabolite EGYT-2760 on isolated rat fundus. Acta Physiol Hung 1991; 78 (3):201–209.
   PubMed Web of Science ®Google Scholar
• AD Munro-Faure, AW Peck, and PA Young. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973; 6 (3):170–176.
   PubMed Web of Science ®Google Scholar
• H Campbell, W Cline, M Evans, J Lloyd, and AW Peck. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1973; 6 (3):170–176.
   PubMed Web of Science ®Google Scholar
• MH Baumann, RD Clark, AG Budzynski, JS Partilla, BE Blough, and RB Rothman. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4, methylenedioxymethamphetamine (MDMA, “Ecstasy”). Neuropsychopharmacology 2005; 30 (3):550–560.
   PubMed Web of Science ®Google Scholar
• MH Baumann, RD Clark, AG Budzynski, JS Partilla, BE Blough, and RB Rothman. Effects of “Legal X” piperazine analogues on dopamine and serotonin release in rat brain. Ann NY Acad Sci 2004; 1025:189–197.
   PubMed Web of Science ®Google Scholar
• P Gee, R Richardson, W Woltersdorf, and G Moore. Prospective study of toxic effects of “herbal party pills” (1-benzylpiperazine) in humans. N Z Med J 2005; 118 (1227):U1784.
   PubMedGoogle Scholar
• H Austin, and E Monasterio. Acute psychosis following ingestion of “Rapture”. Australas Psychiatry 2004; 12 (4):406–408.
   PubMedGoogle Scholar
• M Fonyo, A Guttmann, and K Magyar. Species differences in the in vitro metabolism of EGYT-475, a new antidepressant agent. Pol J Pharmacol Pharm 1987; 39:129–134.
   PubMedGoogle Scholar
• RF Staack, and HH Maurer. Metabolism of designer drugs of abuse. Curr Drug Metab 2005; 6 (3):259–274.
   PubMed Web of Science ®Google Scholar
• RF Staack, LD Paul, D Springer, T Kraemer, and HH Maurer. Cytochrome P450 metabolism of the new designer drug 1–3-trifluromethylphenylpiperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 2004; 67 (2):235–244.
   PubMed Web of Science ®Google Scholar
• Z Nie, X Yuan, SG Madamba, and et al Ethanol decreases glutamatergic synaptic transmission in rat nucleus accumbens in vitro: naloxone reversal. J Pharmacol Exp Ther 1993; 266:1705–1702.
   PubMed Web of Science ®Google Scholar
• E Sanna, M Serra, A Cossu, and et al Chronic ethanol intoxication induces differential effects on GABA and NMDA receptor function in the rat brain. Alcohol Clin Exp Res 1993; 17:115–123.
   PubMed Web of Science ®Google Scholar
• SK Lulkarni, AK Mehta, and MK Ticku. Comparison of anticonvulsant effects of ethanol against NMDA-, kainic acid- and picrotoxin-induced convulsions in rats. Life Sci 1990; 46 (7):481–487.
   PubMed Web of Science ®Google Scholar
• AK Mehta, and MK Ticku. Ethanol potentiation of GABAergic transmission in cultured spinal cord neurons involves GABA A gated chloride channels. J Pharmacol Exp Ther 1988; 246 (2):558–564.
   PubMed Web of Science ®Google Scholar
• RT Khisti, SN Penland, MJ VanDoren, AC Grobin, and AL Morrow. GABAergic neurosteroid modulation of ethanol actions. World J Biol Psychiatry 2002; 3 (2):87–95.
   PubMedGoogle Scholar
• RMH Kater, G Roggin, F Tobin, P Zieve, and FL Iber. Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sci 1968; 258:35–39.
   Web of Science ®Google Scholar
• EM Sellars, and MR Holloway. Drug Kinetics and alcohol ingestion. Clin Pharmacokinetics 1978; 3:440–452.
   PubMed Web of Science ®Google Scholar
• JC Ballenger, and RM Post. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 1978; 133:1–14.
   PubMed Web of Science ®Google Scholar
• SM Wolfe, and M Victor. The relationship of hypomagnesaemia and alkalosis to alcohol withdrawal symptoms. Ann N Y Acad Sci 1969; 162:973–984.
   PubMed Web of Science ®Google Scholar
• M Wikstrom, P Holmgren, and J Ahlner. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 2004; 28 (1):67–70.
   PubMed Web of Science ®Google Scholar
• C Balmelli, H Kupferschmidt, K Rentsch, and M Schneemann. [Fatal brain edema after ingestion of ecstasy and benzylpiperazine]. Dtsch Med Wochenschr 2001; 126 (28–29):809–811. (Abstract) German.
   PubMed Web of Science ®Google Scholar